During corona virus, the FDA has issued an emergency use authorization (EUA) for bamlanivimab, which is a monoclonal antibody given against the spike protein of SARS-CoV-2
Baricitinib or JAK inhibitor is used in combination with remdesivir, in the treatment of suspected or laboratory-confirmed coronavirus disease in hospitalized patients aged 2 years and elderly who require supplemental oxygen, invasive mechanical ventilation. Various other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as possible therapies.
Title : Drug Delivery to Stem Cells in Regenerative Medicine
Esmaiel Jabbari, University of South Carolina, USA
Title : Targeted nanoparticles for diagnostic and theranostic applications
Paul Millner, University of Leeds, UK
Title : Nanostructured Formulations in Skin Cancer: Challenges and Perspectives
Daniela Monti, University of Pisa, Italy
Title : Introducing the Sorush Cancer Treatment Protocol (SCTP)
Sorush Niknamian, Violet Cancer Institute, USA
Title : Hydrogen Sulfide: A Stinky Gas….. and Novel Therapeutic Target for Inflammatory Disease
Madhav Bhatia, University of Otago, Newzealand
Title : Assessment an umbilical cells induced neuroplasticity in patients with schizophrenia using functional MRI
Dmitry Ustyuzhanin, National Medical Research Center of Cardiology, Russia
Title : Evaluation of drug permeability in blood-brain barrier in vitro models
Anna Caprifico, Kingston University, UK
Title : Bryophyllum pinnatum Compounds Inhibit the Oxytocin-Induced Pathways in Human Myometrial Cells
Stefanie Santos, University Hospital Zurich, Switzerland
Title : Cancer: is there any hope?
Ranjita Shegokar, Capnomed GmbH, Germany
Title : Process innovation in the production of smart lipid-polymeric release systems
Annalisa Dalmoro, University of Salerno, Italy